Market Closed -
Nasdaq Stockholm
16:29:34 29/04/2024 BST
|
5-day change
|
1st Jan Change
|
106.9
SEK
|
+3.09%
|
|
+6.58%
|
-15.89%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,930
|
6,972
|
5,904
|
5,507
|
6,822
|
5,566
|
-
|
-
|
Enterprise Value (EV)
1 |
2,177
|
5,976
|
5,162
|
4,971
|
6,815
|
5,441
|
4,373
|
2,365
|
P/E ratio
|
-86
x
|
-14.5
x
|
-11.5
x
|
-11.9
x
|
-14.6
x
|
24.5
x
|
4.52
x
|
2.19
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
15.9
x
|
7,977
x
|
25.7
x
|
6.86
x
|
5.65
x
|
2.88
x
|
1.69
x
|
1.17
x
|
EV / Revenue
|
11.8
x
|
6,837
x
|
22.5
x
|
6.19
x
|
5.65
x
|
2.81
x
|
1.33
x
|
0.5
x
|
EV / EBITDA
|
-77.8
x
|
-15.7
x
|
-9.84
x
|
-11.8
x
|
-18.3
x
|
23.2
x
|
2.9
x
|
0.83
x
|
EV / FCF
|
-24.4
x
|
-12.4
x
|
-11.2
x
|
-15.8
x
|
-
|
23
x
|
3.27
x
|
0.94
x
|
FCF Yield
|
-4.09%
|
-8.06%
|
-8.94%
|
-6.31%
|
-
|
4.35%
|
30.6%
|
107%
|
Price to Book
|
3.72
x
|
5.18
x
|
5.86
x
|
6.48
x
|
20.4
x
|
17.9
x
|
5.81
x
|
2.01
x
|
Nbr of stocks (in thousands)
|
38,708
|
49,942
|
52,342
|
59,573
|
53,672
|
53,672
|
-
|
-
|
Reference price
2 |
75.70
|
139.6
|
112.8
|
92.45
|
127.1
|
103.7
|
103.7
|
103.7
|
Announcement Date
|
14/02/20
|
18/02/21
|
24/02/22
|
23/02/23
|
21/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
184.8
|
0.874
|
229.3
|
802.9
|
1,207
|
1,935
|
3,295
|
4,747
|
EBITDA
1 |
-27.98
|
-379.7
|
-524.5
|
-421.9
|
-373.1
|
234.2
|
1,508
|
2,850
|
EBIT
1 |
-28.02
|
-379.7
|
-524.5
|
-421.9
|
-373.1
|
178.7
|
1,294
|
2,430
|
Operating Margin
|
-15.16%
|
-43,446.22%
|
-228.67%
|
-52.55%
|
-30.91%
|
9.23%
|
39.27%
|
51.18%
|
Earnings before Tax (EBT)
1 |
-32.5
|
-436.2
|
-513.4
|
-409.4
|
-457
|
101.5
|
1,256
|
2,398
|
Net income
1 |
-32.58
|
-433.5
|
-500.3
|
-412.3
|
-466.2
|
85.39
|
1,090
|
2,016
|
Net margin
|
-17.63%
|
-49,598.86%
|
-218.14%
|
-51.35%
|
-38.63%
|
4.41%
|
33.08%
|
42.46%
|
EPS
2 |
-0.8800
|
-9.660
|
-9.840
|
-7.780
|
-8.690
|
4.235
|
22.93
|
47.33
|
Free Cash Flow
1 |
-89.08
|
-481.8
|
-461.6
|
-313.9
|
-
|
236.6
|
1,337
|
2,526
|
FCF margin
|
-48.2%
|
-55,124.49%
|
-201.26%
|
-39.09%
|
-
|
12.23%
|
40.56%
|
53.22%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
101.03%
|
88.64%
|
88.66%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
277.14%
|
122.62%
|
125.32%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
14/02/20
|
18/02/21
|
24/02/22
|
23/02/23
|
21/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
198.2
|
31.2
|
49.73
|
64
|
260.1
|
429
|
191.4
|
269.4
|
294.6
|
451.6
|
383.1
|
434.5
|
515.8
|
622.2
|
EBITDA
1 |
7.856
|
-222.1
|
-208.4
|
-209.8
|
-36.23
|
32.5
|
-180.1
|
-75.17
|
-159.6
|
41.76
|
-59.9
|
-1.933
|
69.87
|
185.9
|
EBIT
1 |
7.856
|
-222.1
|
-208.4
|
-209.8
|
-36.23
|
32.5
|
-180.1
|
-75.17
|
-159.6
|
41.76
|
-31.64
|
-1.908
|
51.69
|
151.4
|
Operating Margin
|
3.96%
|
-711.86%
|
-418.96%
|
-327.88%
|
-13.93%
|
7.57%
|
-94.11%
|
-27.91%
|
-54.17%
|
9.25%
|
-8.26%
|
-0.44%
|
10.02%
|
24.33%
|
Earnings before Tax (EBT)
1 |
6.48
|
-218.5
|
-211.4
|
-192.1
|
-15.96
|
10.07
|
-208
|
-70.66
|
-164.1
|
-14.26
|
-45.62
|
-31.65
|
-1.639
|
59.07
|
Net income
1 |
10.84
|
-219.2
|
-207
|
-192.4
|
-9.111
|
-3.681
|
-187.5
|
-91.93
|
-168.4
|
-18.37
|
-47.16
|
-33.45
|
-3.454
|
57.2
|
Net margin
|
5.47%
|
-702.47%
|
-416.31%
|
-300.67%
|
-3.5%
|
-0.86%
|
-98%
|
-34.13%
|
-57.15%
|
-4.07%
|
-12.31%
|
-7.7%
|
-0.67%
|
9.19%
|
EPS
2 |
-
|
-
|
-
|
-3.620
|
-0.1700
|
-0.0700
|
-3.490
|
-1.710
|
-3.140
|
-0.3400
|
-1.059
|
-0.0782
|
1.224
|
3.481
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
18/11/21
|
24/02/22
|
18/05/22
|
18/08/22
|
14/11/22
|
23/02/23
|
16/05/23
|
17/08/23
|
07/11/23
|
21/02/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
754
|
996
|
742
|
536
|
7.14
|
125
|
1,193
|
3,201
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-89.1
|
-482
|
-462
|
-314
|
-
|
237
|
1,337
|
2,526
|
ROE (net income / shareholders' equity)
|
-4.63%
|
-43.4%
|
-45.1%
|
-46.5%
|
-84.7%
|
21.8%
|
111%
|
87.4%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
20.40
|
27.00
|
19.30
|
14.30
|
6.240
|
5.780
|
17.80
|
51.60
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
18.1
|
173
|
-
|
2.51
|
-
|
31
|
26.6
|
10.2
|
Capex / Sales
|
9.78%
|
19,749.08%
|
-
|
0.31%
|
-
|
1.6%
|
0.81%
|
0.21%
|
Announcement Date
|
14/02/20
|
18/02/21
|
24/02/22
|
23/02/23
|
21/02/24
|
-
|
-
|
-
|
Last Close Price
103.7
SEK Average target price
208
SEK Spread / Average Target +100.58% Consensus |
1st Jan change
|
Capi.
|
---|
| -15.89% | 508M | | +4.06% | 70.44B | | +10.97% | 8.94B | | -14.44% | 4.75B | | +41.60% | 4.5B | | +5.96% | 3.85B | | +23.46% | 2.38B | | -19.32% | 2.34B | | -27.04% | 2.2B | | +7.97% | 1.96B |
Specialty & Advanced Pharmaceuticals
|